The manufacturer of this drug has withdrawn it from the market, and it is not currently available.
Drotrecogin alfa is a recombinant form of human activated protein C, a natural anticoagulant enzyme with potent anti-clot and anti-inflammatory properties. It is administered to hospitalized adults with severe sepsis and multiple organ system failures to decrease the mortality rate. Sepsis is a bacterial infection in the bloodstream that affects the whole body by causing inflamation and clot formation in various organs. Drotrecogin alpha works by decreasing the production of inflammatory chemicals, preventing clot formation and increasing clot breakdown. This drug is given slowly by continuous intravenous infusion and may take as long as four days to administer. Drotrecogin alfa is available only under the brand name Xigris.